DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute, intermediate, and chronic duration exposures; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.
Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Office of Innovation and Analytics
Toxicology Section
1600 Clifton Road, N.E.
Mail Stop S102-1
Atlanta, Georgia 30329-4027

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to “…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

Christopher M. Reh, PhD
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

***DRAFT FOR PUBLIC COMMENT***
## VERSION HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 2022</td>
<td>Draft for public comment released</td>
</tr>
<tr>
<td>June 2009</td>
<td>Addenda released</td>
</tr>
<tr>
<td>December 1998</td>
<td>Final toxicological profile released</td>
</tr>
</tbody>
</table>

***DRAFT FOR PUBLIC COMMENT***
CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Sam Keith, MS, CHP (Lead)  Lauren Brown, MS, DABT
Breanna Alman, MPH   Kaley Beins, MPH
Hannah Derrick, BS   Kerry Diskin, PhD
Andrea Chiger, MPH   Mary Juergens, MPH
Kerry Diskin, PhD   Meghan Lynch, MPH, DSc

ATSDR, Office of Innovation and Analytics, Toxicology Section, Atlanta, GA
Abt Associates, Cambridge, MA

REVIEWERS

Interagency Minimal Risk Level Workgroup:
ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:
ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA

PEER REVIEWERS

1. Kyle Steenland, Ph.D., Professor, Department of Environmental Health Professor, Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia
2. James S. Bus Ph.D., DABT, Fellow ATS, Senior Managing Scientist, Center for Toxicology and Mechanistic Biology, Midland, Michigan
3. Dale Hattis, Ph.D., George Perkins Marsh Institute, Clark University, Worcester, Massachusetts

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers’ comments and determine whether changes will be made to the profile based on comments. The peer reviewers’ comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.
# CONTENTS

DISCLAIMER.................................................................................................................. ii
FOREWORD....................................................................................................................... ii
VERSION HISTORY........................................................................................................ iv
CONTRIBUTORS & REVIEWERS...................................................................................... v
CONTENTS....................................................................................................................... vi
LIST OF FIGURES.......................................................................................................... viii
LIST OF TABLES............................................................................................................. ix
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH......................................................... 1
  1.1 OVERVIEW AND U.S. EXPOSURES..................................................................... 1
  1.2 SUMMARY OF HEALTH EFFECTS.................................................................. 2
  1.3 MINIMAL RISK LEVELS (MRLS).................................................................... 6
CHAPTER 2. HEALTH EFFECTS................................................................................... 9
  2.1 INTRODUCTION.................................................................................................. 9
  2.2 DEATH.............................................................................................................. 58
  2.3 BODY WEIGHT.................................................................................................. 61
  2.4 RESPIRATORY................................................................................................. 62
  2.5 CARDIOVASCULAR.......................................................................................... 64
  2.6 GASTROINTESTINAL....................................................................................... 66
  2.7 HEMATOLOGICAL............................................................................................ 67
  2.8 MUSCULOSKELETAL....................................................................................... 68
  2.9 HEPATIC........................................................................................................... 68
  2.10 RENAL............................................................................................................. 72
  2.11 DERMAL.......................................................................................................... 75
  2.12 OCULAR.......................................................................................................... 76
  2.13 ENDOCRINE.................................................................................................... 77
  2.14 IMMUNOLOGICAL........................................................................................... 78
  2.15 NEUROLOGICAL.............................................................................................. 79
  2.16 REPRODUCTIVE............................................................................................... 88
  2.17 DEVELOPMENTAL........................................................................................... 93
  2.18 OTHER NONCANCER.................................................................................... 95
  2.19 CANCER.......................................................................................................... 96
  2.20 GENOTOXICITY............................................................................................... 97
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS ......................................................................................... 102
  3.1 TOXICOKINETICS............................................................................................. 102
    3.1.1 Absorption.................................................................................................. 102
    3.1.2 Distribution................................................................................................. 103
    3.1.3 Metabolism................................................................................................. 104
    3.1.4 Excretion.................................................................................................... 109
    3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models ................. 109
    3.1.6 Animal-to-Human Extrapolations ............................................................... 110
  3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE ..... 111
  3.3 BIOMARKERS OF EXPOSURE, EFFECT, AND SUSCEPTIBILITY.......................... 114
    3.3.1 Biomarkers of Exposure........................................................................... 115
    3.3.2 Biomarkers of Effect............................................................................... 116
  3.4 INTERACTIONS WITH OTHER CHEMICALS.................................................... 117
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION ............................................. 119

***DRAFT FOR PUBLIC COMMENT***
CHLOROMETHANE

4.1 CHEMICAL IDENTITY ................................................................. 119
4.2 PHYSICAL AND CHEMICAL PROPERTIES .................................. 119
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE ................................ 122
5.1 OVERVIEW ................................................................................. 122
5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL .................. 124
  5.2.1 Production ................................................................. 124
  5.2.2 Import/Export ........................................................... 129
  5.2.3 Use .............................................................................. 130
  5.2.4 Disposal ...................................................................... 131
5.3 RELEASES TO THE ENVIRONMENT .......................................... 132
  5.3.1 Air .............................................................................. 133
  5.3.2 Water .......................................................................... 138
  5.3.3 Soil ............................................................................. 139
5.4 ENVIRONMENTAL FATE .............................................................. 141
  5.4.1 Transport and Partitioning ................................................ 141
  5.4.2 Transformation and Degradation ........................................ 142
5.5 LEVELS IN THE ENVIRONMENT ................................................ 145
  5.5.1 Air .............................................................................. 146
  5.5.2 Water .......................................................................... 149
  5.5.3 Sediment and Soil ........................................................ 152
  5.5.4 Other Media ............................................................... 152
5.6 GENERAL POPULATION EXPOSURE .......................................... 152
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES ................. 154
CHAPTER 6. ADEQUACY OF THE DATABASE ...................................... 156
6.1 EXISTING INFORMATION ON HEALTH EFFECTS ......................... 156
6.2 IDENTIFICATION OF DATA NEEDS ........................................... 157
6.3 ONGOING STUDIES .................................................................. 171
CHAPTER 7. REGULATIONS AND GUIDELINES ................................... 172
CHAPTER 8. REFERENCES .................................................................. 175

APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS............... A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR CHLOROMETHANE............... B-1
APPENDIX C. FRAMEWORK FOR ATSDR’S SYSTEMATIC REVIEW OF DATA FOR
  CHLOROMETHANE ........................................................................ C-1
APPENDIX D. USER’S GUIDE .................................................................. D-1
APPENDIX E. QUICK REFERENCE FOR HEALTH CARE PROVIDERS .............. E-1
APPENDIX F. GLOSSARY ....................................................................... F-1
APPENDIX G. ACRONYMS, ABBREVIATIONS, AND SYMBOLS ...................... G-1

***DRAFT FOR PUBLIC COMMENT***
LIST OF FIGURES

Figure 1-1. Health Effects Found in Animals Following Inhalation Exposure to Chloromethane .......... 5
Figure 1-2. Summary of Sensitive Targets of Chloromethane – Inhalation ........................................ 7
Figure 2-1. Overview of the Number of Studies Examining Chloromethane Health Effects .................. 11
Figure 2-2. Levels of Significant Exposure for Animals and Humans to Chloromethane – Inhalation..... 47
Figure 2-3. Level of Significant Exposure of Animals to Chloromethane – Oral .................................... 57
Figure 3-1. Proposed Scheme for Metabolism of Chloromethane....................................................... 108
Figure 5-1. Number of NPL Sites with Chloromethane Contamination............................................. 122
Figure 6-1. Summary of Existing Health Effect Studies on Chloromethane by Route and Endpoint..... 159
# LIST OF TABLES

Table 1-1. Provisional Minimal Risk Levels for Chloromethane ................................................................. 8  
Table 2-1. Health Effects Evaluated in Humans Exposed to Chloromethane .................................................. 14  
Table 2-2. Levels of Significant Exposure to Chloromethane – Inhalation ...................................................... 23  
Table 2-3. Levels of Significant Exposure of Animals to Chloromethane – Oral ............................................ 56  
Table 2-4. Genotoxicity of Chloromethane In Vivo ........................................................................................ 100  
Table 2-5. Genotoxicity of Chloromethane In Vitro ...................................................................................... 101  
Table 4-1. Chemical Identity of Chloromethane ............................................................................................ 119  
Table 4-2. Physical and Chemical Properties of Chloromethane ................................................................. 120  
Table 5-1. Facilities that Produce, Process, or Use Chloromethane .............................................................. 125  
Table 5-2. Releases to the Environment from Facilities that Produce, Process, or Use Chloromethane ........ 132  
Table 5-3. Releases to the Atmosphere from Facilities that Produce, Process, or Use Chloromethane ......... 133  
Table 5-4. Releases to Soil from Facilities that Produce, Process, or Use Chloromethane ............................ 139  
Table 5-5. Lowest Limit of Detection Based on Standards .......................................................................... 145  
Table 5-6. Chloromethane Levels in Water, Soil, and Air of National Priorities List (NPL) Sites .............. 145  
Table 5-7. Percentile Distribution of Annual Mean Chloromethane Concentrations (ppbv) Measured in  
Ambient Air at Locations Across the United States ...................................................................................... 147  
Table 5-8. Outdoor Air Monitoring Data for Chloromethane ...................................................................... 147  
Table 5-9. Surface Water Monitoring Data for Chloromethane .................................................................. 150  
Table 5-10. Groundwater Monitoring Data for Chloromethane ............................................................... 150  
Table 5-11. Drinking Water Monitoring Data for Chloromethane .............................................................. 151  
Table 5-12. Effluent Monitoring Data for Chloromethane .......................................................................... 151  
Table 5-13. Landfill Leachate Monitoring Data for Chloromethane ........................................................... 151  
Table 5-14. Drinking Water Monitoring Data for Chloromethane .............................................................. 151  
Table 7-1. Regulations and Guidelines Applicable to Chloromethane .......................................................... 173